Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Allogeneic Cart Progress: Platforms, Current Progress and Limitations Publisher Pubmed



A Shokati AMENEH ; M Sanjaripour MARYAM ; M Akhavan Rahnama MAHSHID ; S Hoseinzadeh SAGHAR ; M Vaezi MOHAMMAD ; M Ahmadvand MOHAMMAD
Authors

Source: Frontiers in Immunology Published:2025


Abstract

Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction methods in process of autologous CAR-T cells). In recent years, the additional editing and non-editing technologies are helping to make allogenic CAR-T therapies a hopeful future treatment. Universal off-the-shelf CAR-T cells can be solved key issues include preventing graft-versus-host disease (GVHD) and time consumption and other challenges faced to allogenic CAR-T cells. Here, we have highlighted the improvement in CAR-T development, particularly in engineering allogenic CAR-T, clinical practices related to these, pre-clinical and clinical studies and their successes which investigated in recent 10 years related to treatment of hematological malignancies and cancers by allogenic CAR-T cells. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. The Paths and Challenges of “Off-The-Shelf” Car-T Cell Therapy: An Overview of Clinical Trials, Biomedicine and Pharmacotherapy (2023)
2. Combining the Induced Pluripotent Stem Cell (Ipsc) Technology With Chimeric Antigen Receptor (Car)-Based Immunotherapy: Recent Advances, Challenges, and Future Prospects, Frontiers in Cell and Developmental Biology (2024)
3. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (4)
Hamid Reza Mirzaei (2)
Other Related Docs
4. Effect of Anti-Cd3/Cd28 Dynabeads and Allogeneic Pbmcs on Expansion of Anti-Muc1 Chimeric Receptor T Cells, Journal of Mazandaran University of Medical Sciences (2022)
5. Disturbance in the Reconstitution of Distinct T-Cell Subsets and the Incidence of Gvhd Following Allo-Hsct in Pediatric Patients With Non-Malignant Hematological Disorders, Immunology Letters (2023)
6. Overview and Recent Advances of Regulatory T Cell Therapy in Solid Organ Transplantation, Iranian Journal of Kidney Diseases (2021)
7. Preclinical Studies of Chimeric Antigen Receptor-Modified Natural Killer Cells in Cancer Immunotherapy: A Review, Expert Opinion on Biological Therapy (2022)
8. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
9. Novel Gene Manipulation Approaches to Unlock the Existing Bottlenecks of Car-Nk Cell Therapy, Frontiers in Cell and Developmental Biology (2024)
10. Epigenetic Strategies to Boost Car T Cell Therapy, Molecular Therapy (2021)
11. Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges, International Immunopharmacology (2021)
12. Generation of Cd19-Targeted Chimeric Antigen Receptor T Cells, Archives of Iranian Medicine (2019)
13. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
14. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)
15. The Tricks for Fighting Against Cancer Using Car Nk Cells: A Review, Molecular and Cellular Probes (2022)
16. Bridging the Gap Between Bone Marrow Transplantation and Car-T Cell Therapy in Hematological Cancers, Advances in Experimental Medicine and Biology (2025)
17. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)
18. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
19. Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies, Stem Cell Research and Therapy (2021)
20. Production of Car T-Cells by Gmp-Grade Lentiviral Vectors: Latest Advances and Future Prospects, Critical Reviews in Clinical Laboratory Sciences (2019)